MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
The Malaria Fighter
Sanaria's Dr. Hoffman is featured in Business 2.0 magazine's The Smart List edition.
An Interview with Dr. Stephen Hoffman
In Essential Science Indicators, Dr. Hoffman’s work can be found in the fields of Immunology and Microbiology. Dr. Hoffman is the founder, CEO, and Chief Scientific Officer of Sanaria, Inc. in Rockville, Maryland. In the interview below, he talks with Special Topics correspondent Gary Taubes about his highly cited work in malaria research.
Sanaria Inc. Receives Multi-Year $3 Million U.S. NIH Phase II Small Business Innovation Research Grant for Further Development of its Malaria Vaccine
Sanaria Inc., a Rockville, Maryland privately held company focused on development of an attenuated whole parasite Malaria Vaccine, announced the receipt of a multi-year Phase II Small Business Innovation Research Grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Sanaria Inc. Receives U.S. Army Award for Development of its Malaria Vaccine
Sanaria Inc., a Rockville, Maryland privately held company focused on development of an attenuated whole parasite Malaria Vaccine announced the receipt of a $4.09 million research and development award from the United States Army Medical Research Acquisition Activity Group in Fort Detrick, Maryland.
Sanaria gets $4M in gov’t funds for malaria vaccine
Sanaria has snagged a research grant worth more than $4 million from the Army to work on a malaria vaccine, which the biotech company hopes to have in human testing a year from now.
Hoffman Elected to Membership in the Institute of Medicine of National Academies
tephen L. Hoffman, M.D., Founder, Chief Executive and Scientific Officer of Sanaria Inc., Rockville, Maryland has been elected to membership in the Institute of Medicine (IOM) of the National Academies of Sciences.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.